Teleflex Incorporated TFX

Health CareHealthcare Equipment & SuppliesUnited States of America

Last close 140.67 USD on Nov 2, 2026, +16.2% year to date

Quant rating

Quant rating C Rank 260 of 565 in Health Care

Growth C 241 of 565
Valuation B 131 of 565
Quality C 355 of 565
Revisions C 340 of 565
Momentum C 244 of 565

Wall Street consensus Buy (2.50)Average target 152.81 USD +8.6%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 6.0B
Enterprise value: 8.5B
52-week range: 100.18 – 145.00
3-year range: 100.18 – 256.21
Dividend yield: 0.97%
Beta (5 years): 0.83
Shares outstanding: 42.4M
Next earnings: Nov 5, 2026

About the company

Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters.

Growth and profitability fiscal year ends December 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	1,993	1,700	1,712	2,791	2,810	–
Revenue growth	17.2%	−0.8%	−38.6%	−0.7%	10.7%	−4.7%
EPS (basic, normalized)	6.98	14.01	13.52	13.06	13.33	–
EPS growth	−50.2%	3.6%	3.5%	−2.0%	–	–
Gross margin	56.2%	61.0%	60.7%	54.9%	55.2%	57.6%
Net margin	2.9%	3.4%	8.4%	13.0%	17.3%	9.0%
ROE	1.6%	1.3%	3.4%	9.3%	13.7%	5.9%

Balance sheet, last quarter
Cash & short-term investments (mil)	300
Current ratio	2.60x
Long-term debt (mil)	2,721
Net debt (mil)	2,508
Total equity (mil)	2,905
Net debt / equity	0.86x
Net debt / EBITDA	3.99x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	1,993	+17.2%	4.2x	629	−32.0%	13.5x	6.98	−50.2%	20.2x
2026	2,269	+13.9%	3.7x	513	−18.4%	16.5x	7.22	+3.4%	19.5x
2027	2,366	+4.3%	3.6x	614	+19.7%	13.8x	10.94	+51.7%	12.9x
2028	2,474	+4.6%	3.4x	656	+6.8%	12.9x	12.10	+10.5%	11.6x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	2,269	0.0%	−0.8%	−0.8%	7.22	+0.2%	+7.6%	+7.8%
2027	2,366	0.0%	−1.3%	−1.7%	10.94	0.0%	+3.4%	+5.5%
2028	2,474	0.0%	−1.5%	−2.2%	12.10	0.0%	+3.5%	+3.9%

Earnings surprises EPS beat in 3 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	738	764	764	795	701	781	913	569	548	570
Sales mean (mil)	727	765	770	813	699	771	893	919	533	560
Surprise	+1.5%	−0.1%	−0.7%	−2.2%	+0.2%	+1.2%	+2.3%	−38.1%	+2.8%	+1.9%
EPS reported	3.21	3.42	3.49	3.89	2.91	3.73	3.67	1.93	1.39	1.76
EPS mean	3.07	3.33	3.39	3.86	2.92	3.36	3.38	3.73	1.21	1.28
Surprise	+4.5%	+2.6%	+2.9%	+0.7%	−0.2%	+10.9%	+8.5%	−48.3%	+15.3%	+37.4%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
TFX Teleflex Incorporated	6.0B	3.99x	2.9%	2.05x	19.5x	12.9x	16.5x	13.8x
ABT Abbott Laboratories	190.6B	2.36x	14.7%	3.73x	20.0x	18.6x	16.5x	15.0x
ISRG Intuitive Surgical, Inc.	151.4B	−0.91x	28.4%	9.47x	38.8x	35.0x	26.4x	24.3x
MDT Medtronic PLC	127.0B	1.99x	13.2%	2.53x	16.6x	15.5x	13.2x	12.6x
SYK Stryker Corporation	116.8B	1.65x	12.9%	4.98x	20.7x	18.8x	16.4x	15.3x
BSX Boston Scientific Corporation	64.2B	2.03x	14.4%	2.57x	14.0x	14.2x	12.1x	12.1x
Mean		1.85x	14.4%	4.22x	21.6x	19.2x	16.9x	15.5x
Median		2.01x	13.8%	3.15x	19.7x	17.1x	16.5x	14.4x

Technical analysis

1M+13.3%
3M+3.2%
1Y+14.3%
3Y−30.9%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Teleflex Incorporated, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	1,993	1,700	1,712	2,791	2,810	2,537
Cost of revenue	872	662	672	1,260	1,260	1,212
Gross profit	1,121	1,037	1,040	1,531	1,550	1,325
Selling, general & administrative expenses	720	675	623	864	860	707
Research & development	145	109	114	154	131	120
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	137	150	45.0	14.2	−56.4	75.2
Other operating expenses	0	0	0	0	0	0
Operating income	118	104	259	499	615	423
Net interest income (expense)	−93.8	−77.4	−73.3	−53.4	−55.6	−65.3
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0	0	0	0	0	0
Net income before taxes	24.6	26.3	185	446	559	358
Provision for taxes	−34.0	−30.9	41.9	83.0	74.3	21.9
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	58.5	57.2	144	363	485	336
Extraordinary items	−964	12.5	213	0.2	0.3	−0.5
Net income	−906	69.7	356	363	485	335
EBIT, normalized	256	254	304	514	559	498
EBITDA, normalized	434	415	452	744	796	726
Basic EPS, normalized	6.98	14.01	13.52	13.06	13.33	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Teleflex Incorporated, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	379	290	223	292	445	376
Receivables	346	459	443	409	384	395
Total inventory	404	600	626	579	478	513
Prepaid expenses	156	121	115	132	123	138
Other current assets	654	0	0	0	0	0
Total current assets	1,938	1,471	1,407	1,411	1,429	1,422
Property, plant & equipment	590	612	603	578	573	575
Goodwill	2,305	2,632	2,914	2,537	2,504	2,586
Intangibles	1,524	2,269	2,502	2,306	2,289	2,520
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	590	114	106	95.8	75.9	49.9
Total assets	6,947	7,098	7,533	6,928	6,872	7,153
Liabilities
Accounts payable	130	141	132	127	118	103
Payable/accrued	–	–	–	–	–	–
Accrued expenses	268	317	318	299	312	266
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	100	100	87.5	87.5	110	100
Other current liabilities	264	91.2	68.5	68.7	140	71.2
Total current liabilities	762	649	607	581	680	540
Long-term debt	2,541	1,556	1,728	1,624	1,740	2,378
Minority interest	–	–	–	–	–	–
Other liabilities	519	615	757	701	697	898
Total liabilities	3,822	2,820	3,092	2,906	3,117	3,816
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	48.2	48.1	48.0	48.0	47.9	47.8
Additional paid-in capital	816	781	750	715	693	652
Retained earnings (accumulated deficit)	3,150	4,116	4,110	3,817	3,518	3,096
Treasury stock	−650	−350	−152	−155	−157	−163
Other equity	−239	−317	−314	−404	−347	−297
Total equity	3,125	4,278	4,441	4,022	3,755	3,336
Total liabilities & shareholders' equity	6,947	7,098	7,533	6,928	6,872	7,153

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Teleflex Incorporated, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	−906	69.7	356	363	485	335
Depreciation, depletion & amortization	178	162	148	231	237	227
Deferred taxes	−101	−113	−7.9	−13.0	−110	−32.7
Non-cash items	1,251	497	118	1.4	−88.4	−116
Changes in working capital	−81.1	20.3	−103	−240	127	22.3
Cash from operations	341	636	511	342	651	436
Investing activities
Capital expenditures	−95.2	−90.4	−46.4	−79.2	−71.6	−90.7
Other investing cash flows	−754	−8.9	−575	−179	228	−747
Cash from investing	−849	−99.4	−621	−258	157	−838
Financing activities
Financing cash flow items	−20.5	−0.2	−4.0	−9.2	−41.2	−75.6
Cash dividends paid	−60.3	−63.5	−63.9	−63.8	−63.6	−63.2
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	692	−358	106	−145	−611	594
Cash from financing	612	−422	38.5	−218	−716	455
Foreign exchange effects	23.2	−9.7	2.9	−19.7	−23.1	21.0
Net change in cash	126	105	−69.2	−153	69.2	74.8
Free cash flow	245	545	464	263	580	346

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.